Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | FABP6 | P51161 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PNP | P00491 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049505 | 0.87 | GAA (0.40) | GAAALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL1912692 | 0.82 | GAA (0.44) | GAAALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL18995634 | 0.81 | PKM (0.41) | GAAALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL13544288 | 0.76 | GAA (0.43) | GAAALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL91500 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL28061208 | 0.73 | — | — | |
| SCHEMBL10031019 | 0.72 | PKM (0.51) | GAAALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1107413 | 0.71 | — | — | |
| SCHEMBL4569256 | 0.71 | PKM (0.44) | GAAALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL23563973 | 0.70 | SMN1; SMN2 (0.46) | GAAALDH1A1SMN1; SMN2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306112-A1 | ANTIVIRAL PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306112-A1 | ANTIVIRAL PROTEASE INHIBITORS | ACE, DNPEP, TMPRSS15 | GAA 76/4885ALDH1A1 3653/4885SMN1; SMN2 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.